**Table 1. Early clinical trial data extracted from abstract**

|  |  |
| --- | --- |
| Features | N (%) ormedian [Q1-Q3] |
| Number of patients included (440\*) | 32 [22-51] |
| Dates of publication (462\*) |  |
| Before 1989 | 24 (5%) |
| [1989-1993] | 21 (5%) |
| [1994-1998] | 40 (9%) |
| [1999-2003] | 77 (17%) |
| [2004-2008] | 92 (20%) |
| [2009-2012] | 105 (23%) |
| [2013-2017] | 103 (22%) |
| ECT enrolling all tumor types (462\*) | 312 (68%) |
| ECT enriched in particular tumor type (462\*) | 187 (40%) |
| Drug target mentioned in ECT abstract (462\*) | 370 (80%) |
| Healthy volunteers included (462\*) | 7 (1.5%) |
| Dose expansion cohort (462\*) | 76 (16%) |
| Patients included in expansion cohort (76\*) | 26 [15-37] |
| Molecular biomarker considered (462\*) | 43 (9%) |
| Pathological biomarker considered (462\*) | 28 (6%) |
| Circulating biomarker considered (462\*) | 9 (2%) |
| Clinical anti-tumor activity mentioned (456\*) | 315 (69%) |
| DLT identified or MTD reached (458\*) | 354 (77%) |
| Best objective response rate reported (356\*) | 5% [0-20%] |
| Complete response reported (456\*) | 74 (16%) |
| Grade V† TRAE reported (462\*) | 13 (3%) |
| Cardiac‡ TRAE reported (462\*) | 41 (9%) |
| Neuropsychological‡ TRAE reported (462\*) | 34 (7%) |

[Q1-Q3]: interquartile range. \*number of early clinical trial with available data. ECT: early clinical trial. † according to the Common Terminology Criteria for Adverse Events Version 4.0. TRAE: treatment-related adverse event. For details about features definition, see **Supplementary Method 3**. ‡ defined as any cardiac, neurological, or psychiatric condition mentioned as TRAE in the abstract.